Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds [Yahoo! Finance]
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Yahoo! Finance
On March 3, Tazeen Ahmad from Bank of America Securities increased the price target on Ocular Therapeutix Inc. (NASDAQ:OCUL) from $24 to $27 while maintaining a Buy rating on the stock. This results in a revised upside potential of more than 257% for investors. wavebreakmedia/Shutterstock.com According to Ahmad, a thorough examination of the Phase 3 SOL1 trial results offers compelling evidence in favour of the approval and risk reduction that the diabetic retinopathy program offers through clarifying important questions. On March 3, Clear Street raised its price target on Ocular Therapeutix Inc. (NASDAQ:OCUL) from $21 to $28. The firm maintained its Buy rating on the shares. Clear Street cited positive data from the SOL-1 trial, noting the results support Axpaxli's potential to deliver durable control in wet AMD. Clear Street added that the therapy could address a key unmet need around dosing intervals, with strong efficacy and a favorable safety profile supporting a more co
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in AprilGlobeNewswire
- Ocular Therapeutix Touts Landmark Phase 3 AXPAXLI Win at RBC Ophthalmology Conference [Yahoo! Finance]Yahoo! Finance
- EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug [Yahoo! Finance Canada]Yahoo! Finance Canada
- EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug [Yahoo! Finance]Yahoo! Finance
- What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down [Yahoo! Finance]Yahoo! Finance
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 3/27/26 - Form SCHEDULE
- 2/27/26 - Form 8-K
- 2/25/26 - Form 4
- OCUL's page on the SEC website